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Loss of intercellular adhesion and increased cell motility synergistically facilitate tumor cell invasion. We studied these factors in 90 patients with gastric cancers by using an immunohistochemical technique to detect strong or weak expression of E-cadherin (ECD) and autocrine motility factor receptor (AMFR). Normal gastric mucosa (control) reacted strongly for ECD and weakly for AMFR. In study cases, ECD was weak in 47 cases, and AMFR was strong in 39 cases. Weak ECD and strong AMFR expression were associated with tumor dedifferentiation. AMFR expression correlated positively with depth of invasion but not with lymph node metastasis. ECD expression correlated negatively with lymph node metastasis but not with depth of invasion. A strong inverse correlation was found between ECD and AMFR expression. Tumors with weak ECD and strong AMFR expression displayed a more aggressive phenotype than tumors with strong ECD and weak AMFR expression. The postoperative survival of patients with tumors with weak ECD and strong AMFR expression was significantly shorter than that of other groups. Since they are involved in the pathway to development of tumors with a more aggressive phenotype, ECD and AMFR should be examined to evaluate the biologic potential of gastric cancers.
Because of the limitations of classic clinicopathologic evaluation of malignancy, biologic markers for malignant potential of cancer cells have been studied extensively. Metastasis, which affects the patient's survival most strongly and is acquired during cancer progression, involves many cell properties, including cell adhesion, motility, proteolysis, and angiogenesis. 1 Thus, we have started research on cancer invasion and metastasis in regard to intercellular adhesion regulated by Ecadherin (ECD) and ECD-associated proteins, such as catenins. The reduction of ECD and catenins is associated strongly with cancer invasion and metastasis in vitro and in vivo in cancers of various organs, 2,3 including the esophagus, 4 stomach, 5 breast, 6 and large intestine. 7 This trend is ubiquitous and has been confirmed by many other investigators. 3 However, decline of intercellular adhesion is necessary but not sufficient to induce experimental invasion, and the necessity for acceleration of cell motility has been suggested. 8 Cell motility is another cell property that also contributes to invasion and metastasis. Among many motility factors, Iwazawa et al 9 reported the involvement of hepatocyte growth factor, which is identical to the scatter factor, and Yano et al 10 and Shiozaki et al 11 described epidermal growth factor receptor in cancer invasion in vivo and in vitro.
Autocrine motility factor (AMF) has been purified from the culture media of various tumor cells as a specific motility modifier. 12, 13 The receptor for AMF (AMFR) has been identified as a cell surface glycoprotein (gp78; molecular weight, 78,000) on the B16-F1 melanoma cell line with high metastatic ability. 14, 15 AMFR concentrates on the leading edge of the cell surface, then is phosphorylated and internalized by binding with AMF. 15 Finally, it induces rearrange-ment of integrin, causing cells to move. 16 In this pathway, G protein might be involved, since cell motility is inhibited by a Bordetella pertussis toxin. 16 Up-regulation of AMFR and its implication in cancer progression in human cancers of various origin, including the large intestine, 17 placenta, 18 esophagus, 19 and stomach, 20 has been reported.
Although the mechanism for up-regulation of AMFR in cancer cells has not been well studied, basic experiments using cultured cell lines have shown that loss of cell-cell contact up-regulates the protein expression and promoter activity of AMFR. 21 Since ECD is the strongest intercellular adhesion molecule in epithelial cells, 22 the association between ECD and AMFR has been studied. Thus, the concomitant alteration of loss of ECD and increase of AMFR have been reported in the cultured cell line and bladder cancer tissue. 23 This simultaneous alteration of ECD and AMFR, if they are situated on the common signal, enables us to understand that cancer progression more fluently leads to invasion and metastasis.
In the present study, we studied these 2 molecules simultaneously in gastric cancer by using immunohistochemistry and found a negative correlation and noted the implication for the malignant phenotype. In addition, gastric cancers generally are divided in 2 histologic groups, intestinal type and diffuse type, for which the cause and behavior are different. 24, 25 This difference can be explained partly by the expression pattern of these 2 molecules. Thus, the ECD-AMFR pathway might be involved not only in cancer progression, but also in carcinogenesis.
Materials and Methods
Patients
A total of 90 patients with gastric adenocarcinoma underwent total or distal gastrectomy with regional lymph node dissection at the Department of Surgery II, Osaka University Medical School, Osaka, Japan, from 1992 to 1996. Curative operation with no residual tumor was achieved for all except for 7 patients with peritoneal dissemination. None of them had received preoperative therapy. The age of the patients (68 men and 22 women) ranged from 26 to 83 years (mean ± SD, 61.6 ± 10.9 years).
Immunohistochemical Staining Procedures
Representative samples of tumor and adjacent tissue were snap frozen immediately in a deep freezer, and the tissue sections were stained with H&E and subjected to immunohistochemical studies with AMFR and ECD. Fourmicrometer-thick sections were prepared and mounted on poly-L-lysine-coated slides (Sigma, St Louis, MO) and fixed in 95% ethanol. They were treated with 1% hydrogen peroxide and 0.1% NaN 2 in distilled water for 30 minutes at room temperature to inhibit endogenous peroxidase activity. After washing in a 0.05-mol/L concentration of phosphate-buffered saline (PBS), they were incubated with 3% normal rabbit serum for AMFR or 3% normal mouse serum for ECD for 30 minutes to block nonspecific conjugation in the tissues. The specimens were incubated sequentially with the primary anti-AMFR monoclonal antibody, 3F3A19, or antihuman ECD antibody, HECD1 (Takara Shuzo, Kyoto, Japan), at 4°C overnight. After washing with PBS, they were incubated with biotinylated rabbit antirat IgG for AMFR or rabbit antimouse IgG (Vectastain ABC Kit, Vector, Burlingame, CA), diluted 1:250 in PBS, for 30 minutes at room temperature and with ABC reagent (Vectastain ABC Kit) for 30 minutes at room temperature. The immune conjugate was visualized with a 0.05-mol/L concentration of tris(hydroxymethyl)-aminomethane (Tris)-hydrochloric acid (pH 7.6) containing 0.02% (wt/vol) 3,3´-diaminobenzidine tetrahydrochloride and 0.03% (vol/vol) hydrogen peroxide, and counterstaining was performed with Meyer hematoxylin.
Evaluation of AMFR and ECD Expression
Assessment of staining was performed by at least 2 independent observers (Y.D., H.S.) who had no knowledge of the tumor stage or grade or patient history. The criterion used for the evaluation of AMFR expression was grading according to the population of immunostained tumor cells as described previously. 19, 26 When more than 50% of the tumor cells were stained positively, the tumors were scored as strong. In contrast, when fewer than 50% of the tumor cells were stained, the tumors were scored as weak. The cutoff line for the ECD expression grade was set at 90% of positive cells; thus, tumors with more than 90% and fewer than 90% positivity were evaluated strong and weak, respectively. The immunostaining specificity of these molecules was confirmed by Western blot analysis in previous studies. 4, 19, 26 Histologic Evaluation and Statistical Analysis H&E-stained sections were observed under the microscope, and pathologic factors were identified based on the TNM classification of malignant tumors. 27 For statistical analysis, differences between the 2 groups were assessed by the Mann-Whitney U test, and correlations between 2 parameters were evaluated by the Spearman rank correlation test. Cumulative survival rates were calculated by using the Kaplan-Meier method, 28 and differences in survival curves were assessed by using the log-rank test. For the evaluation of independent prognostic © American Society of Clinical Pathologists indicators, multivariate analysis was performed by using the Cox hazard regression model. 29 
Results
Expression of AMFR and ECD in Gastric Cancers
In noncancerous mucosal epithelium, either with or without gastritis, ECD was expressed strongly at the cell-cell boundary. AMFR was not expressed except in a few cells in the proliferating zone; these cells showed faint staining in the cytoplasm. In gastric cancer cells, AMFR frequently was expressed in the cell surface and cytoplasm, and ECD expression frequently was reduced in a homogenous or heterogeneous fashion ❚Image 1❚. Thus, the alteration in gastric cancers was follows: 39 cases (43%) showed strong expression of AMFR, and 47 cases (52%) showed weak ECD expression.
The expressions of AMFR and ECD molecules were correlated with routine clinicopathologic factors ❚Table 1❚. Strong expression of AMFR was observed more frequently in diffuse-type carcinomas (27/ ). The alterations of these molecules were associated with diffuse-type carcinomas, which imply a loss of differentiation (P = .005 and P = .0219 for AMFR and ECD respectively). Strong expression of AMFR was observed less frequently in superficial (t1) cancer (10/37 [27%]) than in deeper infiltration (t2-4) (29/53 [55%]). There was a significant positive correlation between the depth of invasion and the expression of AMFR (P = .0374); however, the proportion of ECD reduction (weak expression) was similar in superficial and deep infiltrating tumors. For lymph node metastasis, the frequency of strong expression of AMFR was higher in tumors with lymph node metastasis than in those without (20/38 [53%] vs 19/52 [36%]), although the differences were not statistically significant. Weak expression of ECD was associated significantly with lymph node metastasis (P = .0285); weak expression of ECD was noted in 25 (66%) of 38 tumors and 22 (42%) of 52 tumors with and without lymph node metastasis, respectively. It is of interest that the reduction (weak expression) of ECD was associated significantly with lymph node metastasis in intestinal-type carcinomas (P = .001) but not in diffuse-type carcinomas ❚Table 2❚. However, AMFR was not associated with lymph node metastasis even when subdivided by histologic type (data not shown). Peritoneal dissemination was seen more often in tumors with strong expression of AMFR and weak expression of ECD, although this trend was not statistically significant. 
Coexpression Pattern for AMFR and ECD
Implication of AMFR and ECD Expression on Postoperative Survival
Postoperative survival of patients with tumors with weak AMFR was significantly better than for patients with strong expression of AMFR (P = .0174), and survival for patients with strong ECD expression was significantly better than that of their counterparts (P = .0114) ❚Figure 1❚. The status of ECD and AMFR expression and clinicopathologic factors, including histologic type, depth of invasion, and lymph node metastasis, were significant prognostic factors in the univariate analysis ❚Table 5❚. According to the coexpression pattern of AMFR and ECD, the survival rate at 40 months after surgery for patients with tumors that strongly expressed AMFR and weakly expressed ECD was 52%, while the survival rates for the other patterns were 83% to 87% (Figure 1 ). Thus, there was a significant difference in postoperative survival between that strongly expressed AMFR and weakly expressed ECD and the remainder (P = .001). Expression of AMFR and expression of ECD were not independent significant factors in a multivariate analysis because of their strong correlation. However, when tumors were classified into those that strongly expressed AMFR and weakly expressed ECD and the remainder and again subjected to multivariate analysis, strong AMFR and weak ECD expression was a significant independent prognostic factor, as was the depth of invasion. The hazard ratios for strong AMFR and weak ECD expression, t2, and t3 to t4 were 3.676, 6.450, and 12.041, respectively.
Discussion
In the present study, we found overexpression of AMFR in about half of the patients with gastric cancer and association of AMFR with dedifferentiation and deep tumor infiltration. In 1 study that examined the role of AMFR in gastric cancers, 20 ❚Image 1❚ Immunohistochemical expression of autocrine motility factor receptor (AMFR) and E-cadherin (ECD) in normal gastric tubules and gastric cancers. The protein expression of AMFR (A, C, E) and ECD (B, D, F) was detected as brown in consecutive sections of normal gastric tubules (A, B), intestinal type carcinoma (C, D), and diffuse type carcinoma (E, F). Normal gastric tubules did not express AMFR but expressed ECD at the cell-cell boundary. A representative intestinal type carcinoma expressed only a trace amount of AMFR in the cytoplasm (C), but expressed ECD strongly at the cell-cell boundary (D). In contrast, a representative diffuse type carcinoma expressed AMFR strongly on the cell membrane and cytoplasm (E), but did not express ECD (F). The former was classified as AMFR-negative-ECD-positive and the latter as AMFR-positive-ECDnegative (original magnification ×400).
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the observations were consistent with ours. There was a trend for but not a statistically significant association between AMFR expression and lymph node metastasis. The association probably would be significant if the number of cases were increased; however, it is more important to remember that metastasis is a more complicated process than invasion, including disruption of the endothelium, adhesion in the metastatic site, and, probably, neovascularization. 1 Therefore, the contribution of AMFR overexpression might be relatively higher in cancer invasion than in metastasis, so that it was correlated with the depth of invasion but not with lymph node metastasis. In contrast, weak expression of ECD was associated significantly with lymph node metastasis but not with invasion. Although cell adhesion and cell motility contribute to invasion and metastasis, it is interesting that we observed this small but statistically significant difference. We used different cutoff lines to separate the expression of these molecules. Because there was some heterogeneity among cancer colonies for ECD expression, and ECD-negative colonies were considered to be more aggressive, it was advantageous to set the cutoff line at 90% for ECD expression. 5, 26 However, as AMFR was expressed only slightly in normal epithelium and gradually increased in cancer cells, a 50% cutoff was sufficient for separating AMFR expression into 2 groups. 19 The mechanism for regulation of AMFR has not been well studied. The AMFR gene is located on 16q21 30 ; however, so far, amplification of this locus or the AMFR gene itself has not been found. In cultured cell lines, cellcell contact dramatically down-regulated the protein expression and messenger RNA transcription of the AMFR gene. 21 In addition, it was notable that this down-regulation of AMFR did not exist in high metastatic cancer cell lines. 31 Huang et al 32 performed an AMFR promoter assay and found it was suppressed by high cell density. They could not identify the transcription factor but speculated that cMyc was a candidate, since the amount of c-Myc was correlated inversely with cell density. There is another report that retinoic acid down-regulates AMFR expression. 33 Since retinoic acid induces differentiation in various types of cells, differentiation might be another factor that regulates AMFR expression.
These phenomena convinced us that ECD is involved in transcriptional regulation of AMFR. For example, ECD is the strongest cell-cell adhesion molecule. 22 Beta-catenin, an ECD binding protein, is reported to be associated with cMyc transcription. 34 Retinoic acid is known to up-regulate ECD expression. 35 Although the suppression of AMFR transcription by ECD has not been proven directly, the inverse correlation of ECD and AMFR expression has been reported in bladder carcinomas. 30, 36 We found the same relationship in human gastric cancers and, in addition, have shown clearly the clinical significance of their association underlying cancer progression and poor prognosis. Since ECD itself is a strong repressor of cancer invasion and metastasis, 3 the reduction of ECD induces cancer invasion and metastasis, both by the function itself and by the regulatory mechanism for AMFR expression.
Histologically, gastric cancers are classified into differentiated (intestinal type) and undifferentiated (diffuse type). The former arises from intestinal metaplasia of foveolar epithelium and from the tubules, and the latter arises from the proper gastric gland and shows a diffuse growth pattern. 24 As for ECD, it is the characteristic of diffuse type tumors that the function of ECD is disturbed, even in the presence of its protein expression, 5 because of ECD gene mutation or tyrosine phosphorylation of ECD binding proteins. 3 Accordingly, as mentioned previously, loss of cellcell adhesion induces transcription of the AMFR gene. In the present study, we found more AMFR overexpression in diffuse-type tumors than in intestinal-type tumors. This probably is a consequence of a functional or expression disorder of ECD. Consistently, ECD reduction was associated with lymph node metastasis in intestinal-type tumors, while in diffuse-type tumors, the frequencies of lymph node metastasis were similar in both histologic types. Thus, complicated histologic types in gastric cancers and their properties could be understood partly by the expression of ECD and AMFR. Univariate analyses showed that ECD and AMFR are significant prognostic factors. However in an analysis of coexpression, tumors that weakly expressed ECD and strongly expressed AMFR showed the poorest prognosis, and their existence was an independent prognostic factor in multivariate analysis. This suggests that it is important to examine both molecules simultaneously, and the synergistic effect of these molecules seems to be a crucial step for cancer progression.
